Mesothelioma Treatment Options in 2026: What Patients and Families Need to Know

If you or a loved one has been diagnosed with mesothelioma, understanding your treatment options is one of the most important steps you can take. The landscape of mesothelioma care has shifted significantly in recent years — new immunotherapy combinations, updated clinical guidelines, and promising vaccine trials are giving patients more options and better outcomes than ever before.

This guide walks through major treatment approaches available in 2026, from established therapies to emerging clinical trials, so you can have informed conversations with your medical team and make decisions that align with your goals. We are lawyers, not doctors. We are not providing medical advice. The purpose of this article is to help you speak with your doctor in a more informed way.

Standard Mesothelioma Treatments

Treatment for mesothelioma generally falls into three established categories: surgery, chemotherapy, and radiation therapy. Most patients receive a combination of these approaches, known as multimodal therapy, tailored to the stage of the disease, the tumor’s cell type, and the patient’s overall health.

Surgery

For patients diagnosed at an earlier stage, surgery may offer the best chance of removing as much cancer as possible. Two primary surgical procedures are used for pleural mesothelioma (the most common form, affecting the lining of the lungs):

Pleurectomy/decortication (P/D) removes the diseased lining of the lung while preserving the lung itself. This lung-sparing approach has become increasingly preferred by many mesothelioma specialists because it tends to produce fewer complications while achieving similar survival outcomes.

Extrapleural pneumonectomy (EPP) is a more extensive procedure that removes the affected lung, its lining, the diaphragm on that side, and the lining of the heart. While more aggressive, it may be appropriate for select patients whose cancer has not spread beyond the chest. Not every patient is a candidate for surgery. Your oncologist will consider the tumor’s location, how far it has spread, and your lung function and overall fitness when making recommendations.

Source: American Cancer Society

Chemotherapy

Chemotherapy remains a cornerstone of mesothelioma treatment. The standard first-line regimen combines pemetrexed (Alimta) with a platinum-based drug — either cisplatin or carboplatin. This combination produces tumor response rates of approximately 30 to 45 percent, according to published clinical data.

Some patients also receive bevacizumab (Avastin), which blocks blood vessel growth that feeds tumors, alongside chemotherapy. Chemotherapy may be used before surgery (neoadjuvant), after surgery (adjuvant), or as the primary treatment for patients who are not surgical candidates.

Source: Translational Lung Cancer Research

Radiation Therapy

Radiation is most commonly used after surgery to target remaining cancer cells or as a palliative treatment to reduce pain and improve quality of life. Advances in radiation delivery, such as intensity-modulated radiation therapy (IMRT), allow oncologists to target tumors more precisely while limiting damage to surrounding healthy tissue.

Immunotherapy: The Breakthrough Changing Outcomes

Immunotherapy has fundamentally altered the treatment landscape for mesothelioma. Rather than attacking cancer cells directly the way chemotherapy does, immunotherapy helps your own immune system recognize and fight the cancer.

Nivolumab Plus Ipilimumab (CheckMate 743)

The most significant immunotherapy advance for mesothelioma has been the combination of nivolumab (Opdivo) and ipilimumab (Yervoy), which the FDA approved as a first-line treatment in 2020 based on results from the landmark CheckMate 743 clinical trial.

These results are meaningful because mesothelioma has historically had very limited long-term survival rates. A five-year survival rate that more than doubles the chemotherapy benchmark represents genuine progress for patients and families facing this diagnosis.

Pembrolizumab Plus Chemotherapy (KEYNOTE-483)

Another important development is the addition of pembrolizumab (Keytruda) to standard pemetrexed-plus-platinum chemotherapy. The KEYNOTE-483 trial demonstrated that this chemoimmunotherapy combination improved median overall survival compared to chemotherapy alone (17.3 months versus 16.1 months). This approach gives oncologists an additional first-line option, particularly for patients with epithelioid mesothelioma.

What the 2024 ASCO Guideline Update Means for Patients

In late 2024, the American Society of Clinical Oncology (ASCO) published its first major update to mesothelioma treatment guidelines since 2018. Based on a review of 110 peer-reviewed studies conducted between 2016 and 2024, these updated guidelines represent a significant shift in how oncologists approach treatment decisions.

The most important change is that treatment selection now depends heavily on the mesothelioma’s cell type, or histology:

Non-epithelioid mesothelioma (including sarcomatoid and biphasic types): Immunotherapy with nivolumab plus ipilimumab is now the preferred first-line treatment. These subtypes respond poorly to traditional chemotherapy but show significantly better outcomes with immunotherapy.

Epithelioid mesothelioma (the most common subtype): Patients and their oncologists can choose between chemotherapy alone, immunotherapy, or chemoimmunotherapy based on factors like disease burden, other health conditions, and patient preferences.

The guidelines also recommend, for the first time, that all mesothelioma patients be offered germline genetic testing. Certain inherited gene mutations — particularly in genes involved in DNA repair like BAP1 — may affect treatment response and help identify family members at increased risk.

For patients and families, these updated guidelines mean that an accurate pathology diagnosis, including specific histology, is more critical than ever. If you have questions about whether your treatment plan aligns with these current guidelines, discuss them with your oncologist or seek a second opinion from a mesothelioma specialist center.

Emerging Therapies and Clinical Trials

Beyond established treatments, a number of promising new approaches are in active development. Clinical trials give patients access to these therapies, and approximately 94 trials related to mesothelioma are currently active.

UV-1 Cancer Vaccine

One of the most closely watched developments is the UV-1 cancer vaccine, developed by Ultimovacs. In February 2024, the FDA granted Fast Track designation to UV-1 in combination with ipilimumab and nivolumab for patients with inoperable mesothelioma — a recognition that expedites the review process for therapies that address serious conditions.

Phase II trial results (the NIPU trial) showed that patients who received UV-1 alongside immunotherapy had a median overall survival of 15.4 months, compared to 11.1 months for patients who received immunotherapy alone. The objective response rate also nearly doubled — 31% versus 16%. A larger Phase III trial is expected to provide the definitive data needed for potential FDA approval.

CAR T-Cell Therapy

CAR T-cell therapy, which has shown dramatic results in certain blood cancers, is being investigated for mesothelioma. This approach involves modifying a patient’s own immune cells to target specific proteins on the surface of mesothelioma tumors. Early-stage trials are underway at several major cancer centers. We have one client that was recently cured using this therapy.

Tumor Treating Fields (TTFields)

TTFields use low-intensity electric fields delivered through pads placed on the skin to disrupt cancer cell division. This non-invasive approach is being studied as an add-on to chemotherapy for pleural mesothelioma, with early results suggesting improved survival when combined with standard treatment.

Accessing Clinical Trials

Patients in New Jersey and Pennsylvania have access to clinical trials at major cancer centers including Memorial Sloan Kettering, Penn Medicine’s Abramson Cancer Center, and Rutgers Cancer Institute of New Jersey. Your oncologist can help determine whether a clinical trial is appropriate for your situation, or you can search for available trials at ClinicalTrials.gov.

How to Choose the Right Treatment Plan

Choosing a treatment plan for mesothelioma is deeply personal, and there is rarely one “right” answer. The decision involves weighing medical factors, personal priorities, and quality-of-life considerations. Here are key factors to discuss with your medical team:

Histology and staging — Your specific cell type and how far the cancer has spread are the most important medical factors. The updated ASCO guidelines emphasize matching treatment to histology, so make sure your pathology report is thorough and reviewed by a specialist.

Treatment goals — Some patients prioritize extending life as long as possible. Others focus on maintaining quality of life and minimizing side effects. Both approaches are valid, and your treatment plan should reflect your priorities.

Second opinions — Mesothelioma is rare — only about 3,000 people are diagnosed each year in the United States. Because of this, many community oncologists see very few cases. A second opinion from a mesothelioma specialist center can ensure you are aware of all available options, including clinical trials.

Support systems — Treatment for mesothelioma can be physically and emotionally demanding. Consider what support you will need — from caregivers, family, support groups, and palliative care specialists who can help manage symptoms and side effects throughout treatment.

Protecting Your Legal Rights During Treatment

Mesothelioma is caused by asbestos exposure — and in virtually every case, that exposure was preventable. Companies that manufactured, distributed, or used asbestos-containing products knew the dangers and failed to protect workers and their families.

Patients diagnosed with mesothelioma may be entitled to significant compensation through asbestos lawsuits, asbestos trust funds, or both. This compensation can help cover treatment costs, lost income, and the impact on your family’s quality of life.

Every state has a statute of limitations that sets a deadline for filing a mesothelioma claim. In New Jersey and Pennsylvania, you generally have 2 years from the date of diagnosis. Acting promptly is critical — waiting too long can mean losing your right to compensation entirely.

A mesothelioma attorney experienced with asbestos litigation can investigate your exposure history, identify responsible companies, and pursue compensation while you focus on treatment and your family.